Atrium Therapeutics, Inc. Common Stock Capital Reinvestment Ratio
Atrium Therapeutics, Inc. Common Stock capital reinvestment ratio. Atrium Therapeutics, Inc. Common Stock (RNA) has a Capital Reinvestment Ratio of 0.05x as of December 2023, meaning it reinvests 0% of its operating cash flow ($16.50 Million) in capital expenditures ($863.00K). Check RNA cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Atrium Therapeutics, Inc. Common Stock (2019–2019)
Capital reinvestment ratio of Atrium Therapeutics, Inc. Common Stock from 2019 to 2019. This chart tracks Atrium Therapeutics, Inc. Common Stock's Capital Reinvestment Ratio across 1 annual periods. Also explore net asset growth rate of Atrium Therapeutics, Inc. Common Stock to track the company's year-over-year net asset growth rate.
Atrium Therapeutics, Inc. Common Stock Capital Reinvestment Ratio by Year (2019–2019)
Atrium Therapeutics, Inc. Common Stock capital reinvestment ratio by year from 2019 to 2019. For the full cash flow conversion analysis, see RNA operating cash flow.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2019 | 0.09x | $2.49 Million | $235.00K | — |